No Data
No Data
No Data
Pfizer, Takeda Say Four-year Data Support Adcetris as Hodgkin Lymphoma Treatment
Blackstone Weighs Sale Of Japanese Pharma Firm Alinamin: Report
Blackstone Inc. (NYSE:BX) is reportedly considering selling the Japanese consumer healthcare firm Alinamin Pharmaceutical Co., previously owned by Takeda Pharmaceutical Company Limited (NYSE:TAK).Blac
Takeda Pharmaceutical, Pfizer Say Phase 3 Trial Assessing Blood Cancer Combination Therapy Met Co-Primary Endpoints
Takeda Pharmaceutical (TAK) and Pfizer (PFE) said Saturday that a Phase 3 trial assessing the experimental drug Adcetris in combination with chemotherapy to treat patients with Hodgkin lymphoma, a typ
Takeda Says Narcolepsy Drug Meets Main, Secondary Goals in Trial
Takeda Pharmaceutical (TAK) said Monday that its experimental drug, TAK-861, to treat narcolepsy type 1 demonstrated "statistically significant and clinically meaningful" improvements across primary a
Takeda Presents Phase 2b Results for Narcolepsy Treatment at SLEEP 2024
Takeda ((TAK) will present today positive results from its Phase 2b trial of TAK-861 in narcolepsy type 1 (NT1) as late-breaking data presentations at SLEEP 2024, the 38th annual meeting of the Americ
Express News | Saturday, Takeda And Pfizer Announced Presentation Of Phase 3 HD21 Trial Results Evaluating Adcetris (Brentuximab Vedotin) In Combination With Chemotherapy At The American Society Of Clinical Oncology And European Hematology Association Annual Meeting